12:00 AM
 | 
Oct 12, 2009
 |  BC Week In Review  |  Company News  |  Deals

Ipsen, Spirogen, Celtic Therapeutics Holdings L.P. deal

Spirogen regained rights to SG2000 (formerly SJG-136) from Ipsen, which acquired development and commercialization rights to the compound in 2003. Ipsen is eligible for commercial...

Read the full 122 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >